M. Royer, C. Latre, and C. Paul, Infantile scabies, Ann Dermatol Venereol, vol.135, p.87681, 2008.

M. Orkin, Scabies: What???s New?, Curr. Probl. Dermatol, vol.22, p.10511, 1995.
DOI : 10.1159/000424240

D. Bitar, C. Castor, C. D. Fischer, A. Haeghebaert, S. Thiolet et al., La gale est-elle en augmentation en France? État des lieux à partir de diverses enquêtes régionales et nationales – 2008-2010. Saint-Maurice: Institut de veille sanitaire, Disponible sur, 2011.

G. Pouessel, J. Dumortier, and M. Lagrée, Scabies: a common infection in children, Arch Pediatr, vol.19, p.125960, 2012.

R. Hay, A. Steer, D. Engelman, and S. Walton, Scabies in the developing world???-its prevalence, complications, and management, Clinical Microbiology and Infection, vol.18, issue.4, p.31323, 2012.
DOI : 10.1111/j.1469-0691.2012.03798.x

B. Currie and J. Carapetis, Skin infections and infestations in Aboriginal communities in northern Australia, Australasian Journal of Dermatology, vol.22, issue.3, p.13943, 2000.
DOI : 10.1016/S0140-6736(96)90797-7

S. Nanda, B. Reddy, S. Ramji, and D. Pandhi, Analytical Study of Pustular Eruptions in Neonates, Pediatric Dermatology, vol.16, issue.3, p.2105, 2002.
DOI : 10.1046/j.1365-2133.1997.d01-1235.x

D. Dorton and M. Kaufmann, Palmoplantar pustules in an infant. Acropustulosis of infancy, Arch Dermatol, vol.132, pp.13656-13689, 1996.

C. Prins, L. Stucki, L. French, J. Saurat, and R. Braun, Dermoscopy for the in vivo Detection of <i>Sarcoptes scabiei</i>, Dermatology, vol.208, issue.3, p.2413, 2004.
DOI : 10.1159/000077310

A. Dupuy, L. Dehen, E. Bourrat, and C. Lacroix, Accuracy of standard dermoscopy for diagnosing??scabies, Journal of the American Academy of Dermatology, vol.56, issue.1, p.5362, 2007.
DOI : 10.1016/j.jaad.2006.07.025

G. Argenziano, G. Fabbrocini, and M. Delfino, Epiluminescence microscopy. A new approach to in vivo detection of Sarcoptes scabiei, Archives of Dermatology, vol.133, issue.6, p.7513, 1997.
DOI : 10.1001/archderm.133.6.751

R. Cabrera, A. Agar, and M. Dahl, The immunology of scabies, Semin Dermatol, vol.12, p.1521, 1993.

D. Van-neste, E. Mrena, and G. Marchal, Life cycle of scabies mite (Sarcoptes scabiei var. hominis) studied by scanning electron microscopy (author’s transl), Ann Dermatol Venereol, vol.108, p.35561, 1981.

B. Currie and J. Mccarthy, Permethrin and Ivermectin for Scabies, New England Journal of Medicine, vol.362, issue.8, p.71725, 2010.
DOI : 10.1056/NEJMct0910329

L. Arlian, M. Morgan, and J. Neal, Modulation of cytokine expression in human keratinocytes and fibroblasts by extracts of scabies mites, Am J Trop Med Hyg, vol.69, p.6526, 2003.

O. Chosidow, Scabies and pediculosis, The Lancet, vol.355, issue.9206, p.81926, 2000.
DOI : 10.1016/S0140-6736(99)09458-1

H. Reid, B. Birju, Y. Holder, J. Hospedales, and T. Poon-king, Epidemic scabies in four Caribbean islands, 1981???1988, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.84, issue.2, p.298300, 1990.
DOI : 10.1016/0035-9203(90)90296-Q

C. Streeton, J. Hanna, and R. Messer, An epidemic of acute post-streptococcal glomerulonephritis among Aboriginal children, Journal of Paediatrics and Child Health, vol.159, issue.3, p.2458, 1995.
DOI : 10.1016/S0140-6736(73)90324-3

L. Wong, B. Amega, and C. Connors, Outcome of an interventional program for scabies in an Indigenous community, Med J Aust, vol.175, p.36770, 2001.

M. Svartman, J. Finklea, D. Earle, E. Potter, and T. Poon-king, EPIDEMIC SCABIES AND ACUTE GLOMERULONEPHRITIS IN TRINIDAD, The Lancet, vol.299, issue.7744, p.24951, 1972.
DOI : 10.1016/S0140-6736(72)90634-4

R. Hay, R. Estrada-castanon, A. Hernandez, and H. , Wastage of family income on skin disease in Mexico, BMJ, vol.309, issue.6958, p.848, 1994.
DOI : 10.1136/bmj.309.6958.848

H. Conseil-de-la-santé-publique, Recommandations relatives à la conduite à tenir devant un ou plusieurs cas de gale, 2012.

C. Castor and I. Bernadou, Epidémie de gale communautaire Guide d’investigation et d’aide à la gestion. Saint-Maurice (Fra): Institut de veille sanitaire, 2008.

T. Meinking and D. Taplin, Safety of permethrin vs lindane for the treatment of scabies, Arch Dermatol, vol.132, p.95962, 1996.

U. Haustein and B. Hlawa, Treatment of scabies with permethrin versus lindane and benzyl benzoate, Acta Derm. Venereol, vol.69, p.34851, 1989.

B. Lee and P. Groth, Scabies: transcutaneous poisoning during treatment, Pediatrics, vol.59, p.643, 1977.

W. Campbell, Ivermectin as an Antiparasitic Agent for Use in Humans, Annual Review of Microbiology, vol.45, issue.1, p.44574, 1991.
DOI : 10.1146/annurev.mi.45.100191.002305

M. Aziz, S. Diallo, I. Diop, M. Lariviere, and M. Porta, Efficacy and tolerance of ivermectin in human onchocerciasis, Lancet, vol.2, p.1713, 1982.

J. Scheriff, A. Kotze, N. Sangster, and D. Hennessy, Effect of ivermectin on feeding by Haemonchus contortus in vivo, Veterinary Parasitology, vol.128, issue.3-4, p.3416, 2005.
DOI : 10.1016/j.vetpar.2004.12.008

T. Geary, S. Sims, E. Thomas, and L. Vanover, Haemonchus contortus, Exp Parasitol, vol.77, p.8896, 1993.
DOI : 10.1016/bs.apar.2016.02.013

R. Martin, Modes of action of anthelmintic drugs, The Veterinary Journal, vol.154, issue.1, p.1134, 1997.
DOI : 10.1016/S1090-0233(05)80005-X

G. Lankas and L. Gordon, Ivermectin and Abamectin. Toxicology. Campbell WC editor, pp.89-112, 1989.

A. Schinkel, E. Wagenaar, C. Mol, and L. Van-deemter, P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs., Journal of Clinical Investigation, vol.97, issue.11, p.251724, 1996.
DOI : 10.1172/JCI118699

A. Dourmishev, L. Dourmishev, and R. Schwartz, Ivermectin: pharmacology and application in dermatology, International Journal of Dermatology, vol.123, issue.12, p.9818, 2005.
DOI : 10.1016/S0140-6736(94)91625-X

S. Vautier, C. Fernandez, A. Milane, and L. Lacomblez, ABCB1 (P-glycoprotein) and blood-brain barrier: role in neurological diseases and their treatments, J Pharm Clin, vol.25, p.22535, 2006.

Y. Pham and F. Gimenez, Capture, efflux et modulation du transport des médicaments au niveau cérébral, Journal de Pharmacie Clinique, vol.20, p.5263, 2001.

B. Schlosshauer, The blood-brain barrier: Morphology, molecules, and neurothelin, BioEssays, vol.19, issue.5, p.3416, 1993.
DOI : 10.1002/bies.950150508

J. Copin and Y. Gasche, Morphology and physiology of the blood-brain barrier, Ann Fr Anesth Reanim, vol.22, p.20214, 2003.

C. Cordon-cardo, J. O’brien, D. Casals, and L. Rittman-grauer, Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites., Proceedings of the National Academy of Sciences, vol.86, issue.2, p.6958, 1989.
DOI : 10.1073/pnas.86.2.695

S. Nobmann, B. Bauer, and G. Fricker, Ivermectin excretion by isolated functionally intact brain endothelial capillaries, British Journal of Pharmacology, vol.13, issue.Suppl 1, p.7228, 2001.
DOI : 10.1038/sj.bjp.0703762

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572593

R. Juliano and V. Ling, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.455, issue.1, p.15262, 1976.
DOI : 10.1016/0005-2736(76)90160-7

F. Thiebaut, T. Tsuruo, H. Hamada, and M. Gottesman, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues., Proceedings of the National Academy of Sciences, vol.84, issue.21, p.77358, 1987.
DOI : 10.1073/pnas.84.21.7735

A. Didier and F. Loor, The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor, Anti-Cancer Drugs, vol.7, issue.7, p.74551, 1996.
DOI : 10.1097/00001813-199609000-00005

Y. Liu and M. Hu, P-glycoprotein and bioavaibility-implication of polymorphism, Clin Chem Lab Med, vol.38, p.87781, 2000.

U. Vaidhyanathan, Review of Ivermectin in Scabies, Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology, vol.5, issue.6, p.496504, 2001.
DOI : 10.1007/s10227-001-0015-z

C. Burkhart and C. Burkhart, Ivermectin: A Few Caveats Are Warranted Before Initiating Therapy for Scabies, Archives of Dermatology, vol.135, issue.12, p.154950, 1999.
DOI : 10.1001/archderm.135.12.1549

C. Guzzo, C. Furtek, A. Porras, and C. Chen, Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects, Journal of Clinical Pharmacology, vol.42, issue.10, p.112233, 2002.
DOI : 10.1177/009127002401382731

M. Pacqué, B. Muñoz, B. Greene, and A. White, Safety of and compliance with community-based ivermectin therapy, The Lancet, vol.335, issue.8702, p.137780, 1990.
DOI : 10.1016/0140-6736(90)91253-7

E. Hey, Part Introduction, in Neonatal Formulary 6: Drug Use in Pregnancy and the First Year of Life, 2011.

D. Giudice, P. , and M. P. , Ivermectin a new therapeutic weapon in dermatology, Arch Dermatol, vol.135, p.7056, 1999.

E. Ottesen, P. Hooper, M. Bradley, and G. Biswas, The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years, PLoS Neglected Tropical Diseases, vol.367, issue.10, p.317, 2008.
DOI : 10.1371/journal.pntd.0000317.s001

E. Macotela-ruiz and G. Pena-gonzalez, The treatment of scabies with oral ivermectin, Gac Med Mex, vol.129, p.2015, 1993.

T. Meinking, D. Taplin, J. Hermida, R. Pardo, and F. Kerdel, The Treatment of Scabies with Ivermectin, New England Journal of Medicine, vol.333, issue.1, p.2630, 1995.
DOI : 10.1056/NEJM199507063330105

C. Dunne, C. Malone, and J. Whitworth, A field study of the effects of ivermectin on ectoparasites of man, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.85, issue.4, p.5501, 1991.
DOI : 10.1016/0035-9203(91)90255-W

S. Kar, J. Mania, and S. Patnaik, The use of ivermectin for scabies, Natl Med J India, vol.7, p.156, 1994.

A. Dourmishev, D. Serafimova, and L. Dourmishev, Efficacy and tolerance of oral ivermectin in scabies, Journal of the European Academy of Dermatology and Venereology, vol.335, issue.3, p.24751, 1998.
DOI : 10.1046/j.1365-4362.1998.00330.x

M. Buffet and N. Dupin, Current treatments for scabies, Fundamental and Clinical Pharmacology, vol.9, issue.2, p.21725, 2003.
DOI : 10.1001/archderm.133.10.1314

E. Chouela, A. Abeldano, and G. Pellerano, Equivalent Therapeutic Efficacy and Safety of Ivermectin and Lindane in the Treatment of Human Scabies, Archives of Dermatology, vol.135, issue.6, p.6515, 1999.
DOI : 10.1001/archderm.135.6.651

P. Glaziou, J. Cartel, P. Alzieu, and C. Briot, Comparison of ivermectin and benzyl benzoate for treatment of scabies, Trop Med Parasitol, vol.44, p.3312, 1993.

V. Madan, K. Jaskiran, U. Gupta, and D. Gupta, Oral Ivermectin in Scabies Patients: A Comparison with 1% Topical Lindane Lotion, The Journal of Dermatology, vol.7, issue.9, p.4814, 2001.
DOI : 10.1111/j.1346-8138.2001.tb00015.x

S. Huffam and B. Currie, Ivermectin for Sarcoptes scabiei hyperinfestation, International Journal of Infectious Diseases, vol.2, issue.3, p.1524, 1998.
DOI : 10.1016/S1201-9712(98)90118-7

URL : http://doi.org/10.1016/s1201-9712(98)90118-7

M. Xu, M. Molento, W. Blackhall, and P. Ribeiro, Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog1, Mol Biochem Parasitol, vol.91, p.32735, 1998.

B. Currie, P. Harumal, M. Mckinnon, and S. Walton, First Documentation of In Vivo and In Vitro Ivermectin Resistance in Sarcoptes scabiei, Clinical Infectious Diseases, vol.39, issue.1, p.812, 2004.
DOI : 10.1086/421776

L. Fox, Ivermectin: uses and impact 20 years on, Current Opinion in Infectious Diseases, vol.19, issue.6, p.58893, 2006.
DOI : 10.1097/QCO.0b013e328010774c

P. Brooks and R. Grace, Ivermectin is better than benzyl benzoate for childhood scabies in developing countries, Journal of Paediatrics and Child Health, vol.135, issue.4, p.4014, 2002.
DOI : 10.1046/j.1525-1470.1999.016001069.x

D. Mar-saez-de-ocariz, M. Mckinster, and C. , Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin, Clinical and Experimental Dermatology, vol.349, issue.4, p.2647, 2002.
DOI : 10.1046/j.1365-4362.1999.00662.x

A. Patel, P. Hogan, and B. Walder, Crusted scabies in two immunocompromised children: Successful treatment with oral ivermectin, Australasian Journal of Dermatology, vol.40, issue.1, p.3740, 1999.
DOI : 10.1001/archderm.132.8.901

M. Larralde, L. Mijelshon, A. Gonzalez, and E. Mora, Ivermectin-responsive crusted scabies in four patients, Pediatr Dermatol, vol.16, p.6970, 1999.

H. Gladstone and G. Darmstadt, Crusted Scabies in an Immunocompetent Child: Treatment with Ivermectin, Pediatric Dermatology, vol.132, issue.2, p.1448, 2000.
DOI : 10.1097/00006454-199810000-00017

S. Cestari, V. Petri, and O. Rotta, Oral Treatment of Crusted Scabies with Ivermectin: Report of Two Cases, Pediatric Dermatology, vol.40, issue.5, p.4104, 2000.
DOI : 10.1056/NEJM199503023320917

V. Marlière, S. Roul, C. Labrèze, and A. Taïeb, Crusted (Norwegian) scabies induced by use of topical corticosteroids and treated successfully with ivermectin, The Journal of Pediatrics, vol.135, issue.1, p.1224, 1999.
DOI : 10.1016/S0022-3476(99)70342-2

F. Jaramillo-ayerbe and J. Berrio-munoz, Ivermectin for Crusted Norwegian Scabies Induced by Use of Topical Steroids, Archives of Dermatology, vol.134, issue.2, p.1435, 1998.
DOI : 10.1001/archderm.134.2.143

T. Meinking and G. Elgart, Scabies therapy for the millenium, Pediatr Dermatol, vol.17, p.1546, 2000.

G. Lawrence, J. Leafasia, J. Sheridan, and S. Hills, Control of scabies, skin sores and haematuria in children in the Salomon Islands: another role for ivermectin, Bull World Health Organ, vol.83, p.3442, 2005.

V. Jairo, N. Ahumada, and F. Gonzalez, Pediculosis capitis tratamiento de la escabiasis con ivermectina, Act Ter Dermatol, vol.20, p.99103, 1997.

O. Chosidow, B. Giraudeau, J. Cottrell, and A. Izri, Oral Ivermectin versus Malathion Lotion for Difficult-to-Treat Head Lice, New England Journal of Medicine, vol.362, issue.10, p.896905, 2010.
DOI : 10.1056/NEJMoa0905471

R. Fawcett, Ivermectin use in scabies, Am Fam Physician, vol.68, p.108992, 2003.

R. Barkwell and S. Shields, Deaths associated with ivermectin treatment of scabies, The Lancet, vol.349, issue.9059, p.11445, 1997.
DOI : 10.1016/S0140-6736(05)63020-6

B. Currie, S. Huffam, D. O’brien, and S. Walton, Ivermectin for scabies, The Lancet, vol.350, issue.9090, p.1551, 1997.
DOI : 10.1016/S0140-6736(05)63983-9

D. Giudice, P. Marty, P. Gari-toussaint, M. , L. Fichoux et al., Ivermectin in Elderly Patients, Archives of Dermatology, vol.135, issue.3, p.3512, 1999.
DOI : 10.1001/archderm.135.3.351

R. Reintjes and C. Hoek, Deaths associated with ivermectin for scabies, The Lancet, vol.350, issue.9072, pp.215-216, 1997.
DOI : 10.1016/S0140-6736(05)62377-X

P. Coyne and D. Addiss, Deaths associated with ivermectin for scabies, The Lancet, vol.350, issue.9072, p.2156, 1997.
DOI : 10.1016/S0140-6736(05)62378-1

K. Mealey, S. Bentjen, J. Gay, and G. Cantor, Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene, Pharmacogenetics, vol.11, issue.8, p.72733, 2001.
DOI : 10.1097/00008571-200111000-00012

A. Roulet, O. Puel, S. Gesta, J. Lepage, and M. Drag, MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin, European Journal of Pharmacology, vol.460, issue.2-3, p.8591, 2003.
DOI : 10.1016/S0014-2999(02)02955-2

J. Geyer, O. Gavrilova, and E. Petzinger, Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein-and bcrp-deficient knockout mice, J Vet Pharmacol Ther, vol.32, p.8796, 2009.

A. Schinkel, J. Smit, and O. Van-tellingen, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs, Cell, vol.77, issue.4, p.491502, 1994.
DOI : 10.1016/0092-8674(94)90212-7

A. Schinkel, C. Mol, E. Wagenaar, and L. Van-deemter, Multidrug resistance and the role of P-glycoprotein knockout mice, European Journal of Cancer, vol.31, issue.7-8, p.12958, 1995.
DOI : 10.1016/0959-8049(95)00130-B

N. Kioka, J. Tsubota, Y. Kakehi, and T. Komano, P-Glycoprotein gene (MDR1) cDNA from human adrenal: Normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance, Biochemical and Biophysical Research Communications, vol.162, issue.1, p.22431, 1989.
DOI : 10.1016/0006-291X(89)91985-2

N. Macdonald and A. Gledhill, Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans, Archives of Toxicology, vol.63, issue.7, p.55363, 2007.
DOI : 10.1007/s00204-007-0193-6

C. Verstuyft, M. Schwab, E. Schaeffeler, and R. Kerb, Digoxin pharmacokinetics and MDR1 genetic polymorphisms, European Journal of Clinical Pharmacology, vol.71, issue.12, p.80912, 2003.
DOI : 10.1067/mcp.2002.121152

M. Brunner, O. Langer, R. Sunder-plassmann, and G. Dobrozemsky, Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans, Clin Pharmacol Ther, vol.78, p.18290, 2005.

R. Antonucci and A. Porcella, Current pharmacotherapy in the newborn, Research and Reports in Neonatology, vol.2, pp.85-94, 2012.
DOI : 10.2147/RRN.S28746

N. Saunders, S. Liddelow, and K. Dziegielewska, Barrier Mechanisms in the Developing Brain, Frontiers in Pharmacology, vol.3
DOI : 10.3389/fphar.2012.00046

N. Saunders, M. Habgood, and K. Dziegielewska, BARRIER MECHANISMS IN THE BRAIN, II. IMMATURE BRAIN, Clinical and Experimental Pharmacology and Physiology, vol.26, issue.2, p.8591, 1999.
DOI : 10.1007/s004290050042

K. Møllgård and N. Saunders, THE DEVELOPMENT OF THE HUMAN BLOOD-BRAIN AND BLOOD-CSF BARRIERS, Neuropathology and Applied Neurobiology, vol.33, issue.4, p.33758, 1986.
DOI : 10.1002/cne.902040105

C. Ek, K. Dziegielewska, M. Habgood, and N. Saunders, Barriers in the developing brain and Neurotoxicology, NeuroToxicology, vol.33, issue.3, pp.586-604, 2012.
DOI : 10.1016/j.neuro.2011.12.009

U. Schumacher and K. Mollgård, The multidrug-resistance P-glycoprotein (Pgp, MDR1 ) is an early marker of blood-brain barrier development in the microvessels of the developing human brain, Histochemistry and Cell Biology, vol.108, issue.2, p.17982, 1997.
DOI : 10.1007/s004180050159

M. Ceckova-novotna, P. Pavek, and F. Staud, P-glycoprotein in the placenta: Expression, localization, regulation and function, Reproductive Toxicology, vol.22, issue.3, p.40010, 2006.
DOI : 10.1016/j.reprotox.2006.01.007

G. Lankas, L. Wise, and M. Cartwright, Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice, Reproductive Toxicology, vol.12, issue.4, p.45763, 1998.
DOI : 10.1016/S0890-6238(98)00027-6

J. Chippaux, N. Gardon-wendel, J. Gardon, and J. Ernould, Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.87, issue.3, p.318, 1993.
DOI : 10.1016/0035-9203(93)90146-H

M. Pacqué, B. Munoz, G. Poetschke, and J. Foose, Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution, The Lancet, vol.336, issue.8729, p.14869
DOI : 10.1016/0140-6736(90)93187-T

J. Gyapong, M. Chinbuah, and M. Gyapong, Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis, Tropical Medicine and International Health, vol.48, issue.12, p.1093101, 2003.
DOI : 10.1016/0140-6736(90)93187-T

O. Doumbo, G. Soula, G. Kodio, and M. Perrenoud, Ivermectin and pregnancy in mass treatment in Mali, Bull Soc Pathol Exot, vol.85, p.24751, 1992.

D. Bitar, J. Thiolet, and S. Haeghebaert, La gale en France entre 1999??et 2010??: augmentation de l???incidence et implications en sant?? publique, Annales de Dermatologie et de V??n??r??ologie, vol.139, issue.6-7, pp.428-462, 2012.
DOI : 10.1016/j.annder.2012.01.023

A. Downs, I. Harvey, and C. Kennedy, The epidemiology of head lice and scabies in the UK, Epidemiology and Infection, vol.122, issue.3
DOI : 10.1017/S0950268899002277

M. Royer, C. Latre, C. Paul, and J. Mazereeuw-hautier, La gale du nourrisson, Annales de Dermatologie et de V??n??r??ologie, vol.135, issue.12, pp.876-81, 2008.
DOI : 10.1016/j.annder.2008.06.006

R. Hay, A. Steer, D. Engelman, and S. Walton, Scabies in the developing world???-its prevalence, complications, and management, Clinical Microbiology and Infection, vol.18, issue.4, pp.313-336, 2012.
DOI : 10.1111/j.1469-0691.2012.03798.x

B. Lee and P. Groth, Scabies: transcutaneous poisoning during treatment, Pediatrics, vol.59, p.643, 1977.

R. Ruiz-maldonado, Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin, Clin Exp Dermatol, vol.27, pp.264-271, 2002.

S. Cestari, V. Petri, O. Rotta, and M. Alchorne, Oral Treatment of Crusted Scabies with Ivermectin: Report of Two Cases, Pediatric Dermatology, vol.40, issue.5, pp.410-414, 2000.
DOI : 10.1056/NEJM199503023320917

A. Patel, P. Hogan, and B. Walder, Crusted scabies in two immunocompromised children: Successful treatment with oral ivermectin, Australasian Journal of Dermatology, vol.40, issue.1, pp.37-40, 1999.
DOI : 10.1001/archderm.132.8.901

M. Larralde, L. Mijelshon, and A. Gonzalez, VERMECTIN-RESPONSIVE CRUSTED SCABIES IN FOUR PATIENTS, Pediatric Dermatology, vol.44, issue.1, pp.69-70, 1999.
DOI : 10.1016/0035-9203(91)90255-W

V. Marliere, S. Roul, C. Labreze, and A. Taieb, Crusted (Norwegian) scabies induced by use of topical corticosteroids and treated successfully with ivermectin, The Journal of Pediatrics, vol.135, issue.1, pp.122-126, 1999.
DOI : 10.1016/S0022-3476(99)70342-2

F. Jaramillo-ayerbe and J. Berrio-munoz, Ivermectin for Crusted Norwegian Scabies Induced by Use of Topical Steroids, Archives of Dermatology, vol.134, issue.2, pp.143-148, 1998.
DOI : 10.1001/archderm.134.2.143

H. Gladstone and G. Darmstadt, Crusted Scabies in an Immunocompetent Child: Treatment with Ivermectin, Pediatric Dermatology, vol.132, issue.2, pp.144-152, 2000.
DOI : 10.1097/00006454-199810000-00017

N. Saunders, M. Habgood, and K. Dziegielewska, Barrier mechanisms in the brain, II

J. Chippaux, N. Gardon-wendel, J. Gardon, and J. Ernould, Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.87, issue.3, p.318, 1993.
DOI : 10.1016/0035-9203(93)90146-H